• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Effects of COVID-19 in lymphoid malignancies.新型冠状病毒肺炎对淋巴系统恶性肿瘤的影响。
World J Virol. 2021 Nov 25;10(6):329-331. doi: 10.5501/wjv.v10.i6.329.
2
Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report.尽管患有2019冠状病毒病（CoVID-19）且严重急性呼吸综合征冠状病毒2（SARS-CoV-2）持续复制，嵌合抗原受体（CAR）T细胞疗法仍成功治疗侵袭性淋巴瘤——病例报告
Front Oncol. 2021 Jul 14;11:706431. doi: 10.3389/fonc.2021.706431. eCollection 2021.
3
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review.淋巴瘤患者中的新型冠状病毒肺炎（严重急性呼吸综合征冠状病毒2感染）：综述
World J Virol. 2021 Nov 25;10(6):312-325. doi: 10.5501/wjv.v10.i6.312.
4
[Practical guidance for the management of patients with hematological disorders during the coronavirus disease 2019 pandemic in Japan].[日本2019冠状病毒病大流行期间血液系统疾病患者管理的实用指南]
Rinsho Ketsueki. 2021;62(8):1178-1185. doi: 10.11406/rinketsu.62.1178.
5
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
6
Impact of COVID-19 in patients with lymphoid malignancies.新型冠状病毒肺炎对淋巴系统恶性肿瘤患者的影响。
World J Virol. 2021 May 25;10(3):97-110. doi: 10.5501/wjv.v10.i3.97.
7
Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up.一名慢性淋巴细胞白血病（CLL）合并新型冠状病毒肺炎（COVID-19）患者在69天随访期间的低体液免疫反应及对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的清除无效
Front Oncol. 2020 Jul 3;10:1272. doi: 10.3389/fonc.2020.01272. eCollection 2020.
8
[Practical management of the patients with hematological diseases during the COVID-19 pandemic in Japan].[日本新冠疫情期间血液系统疾病患者的实际管理]
Rinsho Ketsueki. 2021;62(2):115-124. doi: 10.11406/rinketsu.62.115.
9
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19（Sars-Cov-2）的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
10
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.SARS-CoV-2 感染免疫功能低下患者：体液免疫与细胞免疫。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000862.

本文引用的文献

1
Impact of COVID-19 in patients with lymphoid malignancies.新型冠状病毒肺炎对淋巴系统恶性肿瘤患者的影响。
World J Virol. 2021 May 25;10(3):97-110. doi: 10.5501/wjv.v10.i3.97.
2
Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the "flare phenomenon" to the "abscopal effect".新型冠状病毒感染后滤泡性淋巴瘤完全缓解：从“flare现象”到“远隔效应”
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2652-2654. doi: 10.1007/s00259-021-05275-6. Epub 2021 Feb 27.
3
COVID-19 in Patients With Hematologic-Oncologic Risk Factors: Complications in Three Patients.血液肿瘤危险因素患者的COVID-19：三例患者的并发症
Cureus. 2020 Dec 13;12(12):e12064. doi: 10.7759/cureus.12064.
4
Major rise of a chronic lymphoid leukemia clone during the course of COVID-19.在新冠病毒病病程中慢性淋巴细胞白血病克隆显著增殖。
Int J Lab Hematol. 2021 Apr;43(2):e82-e83. doi: 10.1111/ijlh.13383. Epub 2020 Nov 8.
5
Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.一名接受康复期血浆治疗的 COVID-19 感染淋巴瘤患者出现病毒长时间脱落。
Transfus Apher Sci. 2020 Oct;59(5):102871. doi: 10.1016/j.transci.2020.102871. Epub 2020 Jul 3.
6
Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma.新冠康复者血浆在一名近期接受滤泡性淋巴瘤治疗的患者中的成功应用。
Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):66-68. doi: 10.1016/j.clml.2020.06.012. Epub 2020 Jun 25.
7
Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience.血液系统恶性肿瘤的COVID-19患者中SARS-CoV-2 RNA的不良预后和长期持续存在；国王学院医院的经验。
Br J Haematol. 2020 Sep;190(5):e279-e282. doi: 10.1111/bjh.16935. Epub 2020 Aug 10.
8
How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation.2019新型冠状病毒（COVID-19）疫情期间如何管理淋巴系统恶性肿瘤：巴西特别工作组建议
Hematol Transfus Cell Ther. 2020 Apr-Jun;42(2):103-110. doi: 10.1016/j.htct.2020.04.002. Epub 2020 Apr 17.
9
Complete spontaneous remission of diffuse large B-cell lymphoma of the maxillary sinus after concurrent infections.上颌窦弥漫性大B细胞淋巴瘤在并发感染后完全自发缓解。
Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):455-8. doi: 10.1016/j.clml.2012.06.007. Epub 2012 Sep 29.

新型冠状病毒肺炎对淋巴系统恶性肿瘤的影响。

Effects of COVID-19 in lymphoid malignancies.

作者信息

Özdemir Öner

机构信息

Division of Pediatric Allergy and Immunology, Sakarya University Medical Faculty, Adapazarı 54100, Sakarya, Turkey.

出版信息

World J Virol. 2021 Nov 25;10(6):329-331. doi: 10.5501/wjv.v10.i6.329.

DOI:10.5501/wjv.v10.i6.329
PMID:34909407
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8641039/
Abstract

I will have a couple of comments on the issues elaborated in the article titled as 'Impact of COVID-19 in patients with lymphoid malignancies'. First, the author did not emphasize and overlook the prolonged persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in coronavirus disease 2019 (COVID-19) patients with hematological malignancies. Second, the rise of a chronic lymphoid leukemia clone in COVID-19 was not mentioned by the authors. Third, achieving a complete remission in asymptomatic COVID-19 patients with follicular lymphoma in partial remission after bendamustine-based therapy is not specific to this lymphoma subtype. Fourth, follicular lymphoma does not always undergo complete remission with SARS-CoV-2 infection. Our aim is to help the authors to discuss and clarify these issues a little more in COVID-19 patients with hematological malignancies.

摘要

对于题为《COVID-19对淋巴系统恶性肿瘤患者的影响》一文中阐述的问题，我有几点看法。首先，作者没有强调且忽略了严重急性呼吸综合征冠状病毒2（SARS-CoV-2）RNA在2019冠状病毒病（COVID-19）血液系统恶性肿瘤患者中持续存在的时间延长这一情况。其次，作者未提及COVID-19中慢性淋巴细胞白血病克隆的出现。第三，在基于苯达莫司汀的治疗后处于部分缓解的滤泡性淋巴瘤无症状COVID-19患者中实现完全缓解并非该淋巴瘤亚型所特有。第四，滤泡性淋巴瘤并非总是因SARS-CoV-2感染而实现完全缓解。我们的目的是帮助作者在COVID-19血液系统恶性肿瘤患者中对这些问题进行更多的讨论和阐明。